A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Active:	No
Cancer Type:	Unknown Primary	NCT ID:	NCT04710576
Trial Phases:	Phase II	Protocol IDs:	SNDX-6352-0504 (primary) NCI-2021-01333
Eligibility:	2 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Syndax Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT04710576

Summary

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3
different dose levels in participants with recurrent or refractory active chronic graft
versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Objectives

AGAVE-201 is a Phase 2, open-label, randomized, multicenter study to evaluate the efficacy,
safety, and tolerability of axatilimab in participants with recurrent or refractory active
cGVHD after failure of at least 2 prior lines of systemic therapy due to progression of
disease, intolerability, or toxicity.

Participants will be randomized to receive 1 of 3 different axatilimab treatment regimens in
28-day treatment cycles for up to 2 years.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.